Browse the evidence

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

Weight management interventions delivered by non-medical practitioners (e.g., health coaches) are as effective as those delivered by general practitioners (GPs) or nurses.

You don't need to see a doctor for every weight management visit. Programs led by health coaches or nurses, especially when supervised by a doctor, are just as effective. Focus on finding a program with good support and regular contact.

Tirzepatide treatment in adults with obesity or overweight results in a body composition change where approximately 75% of total weight loss is fat mass and 25% is lean mass, a proportion consistent with placebo and other weight loss modalities.

If you take tirzepatide, expect to lose about 3 pounds of fat for every 1 pound of muscle. This is the same ratio you would get from dieting alone. You do not need to worry that the medication is uniquely damaging to your muscles. To protect your strength, focus on the recommended lifestyle changes: eat 500 calories less per day and move for 150 minutes a week.

Low-carbohydrate weight-reducing diets produce greater short-term weight loss (3-12 months) than balanced-carbohydrate diets in overweight/obese adults without type 2 diabetes, but this advantage disappears after 12 months.

If you want to lose weight quickly, a low-carb diet might give you a slight edge over a balanced diet in the first year. However, after a year, it offers no advantage over a balanced diet. Choose the diet you can stick to, as long-term weight loss is similar regardless of carb intake.

Low-carbohydrate diets improve triglyceride levels more than balanced-carbohydrate diets in overweight/obese adults without type 2 diabetes, regardless of weight loss duration.

If you have high triglycerides, a low-carb diet may help lower them more effectively than a balanced diet, even if your weight loss is similar.

Meal replacements improve satiety and reduce cravings during caloric restriction through mechanisms like stimulus narrowing and ketosis, despite expected hormonal changes.

You might worry that eating less will make you hungry, but using meal replacements can actually help control hunger. By limiting food choices (stimulus narrowing) and potentially inducing ketosis, MRs can reduce cravings and make sticking to a diet easier.

Sustained weight loss (≥7% at 1 year) is associated with significantly lower HbA1c levels at 10 years compared to weight regain, although A1c may still rise slightly from baseline.

If you lose weight through lifestyle changes, keeping it off is crucial for long-term blood sugar control. Even if your blood sugar rises slightly from its lowest point, keeping 7% or more weight off keeps it significantly lower than if you regain the weight. This helps protect your kidneys over the next decade.

Bariatric surgery (RYGB or SG) produces significantly greater weight loss and higher treatment success rates than structured medical treatment including very low energy diet (VLED) at 2-year follow-up, though both interventions improve cardiovascular risk factors and safety profiles similarly.

For individuals with BMI ≥35, bariatric surgery (RYGB or SG) is significantly more effective than structured medical treatment (including very low energy diets) for achieving substantial weight loss and metabolic improvement at 2 years. However, medical treatment remains a viable option that yields positive cardiovascular and safety outcomes, with about 45% of patients achieving >10% weight loss. The choice involves trading the higher efficacy of surgery for the non-invasiveness of medical management.

Baseline anthropometry (initial BMI/weight) is the strongest predictor of treatment success for both surgical and medical obesity interventions, followed by psychiatric health and lifestyle factors.

Your starting weight and BMI are the best predictors of how much weight you will lose, regardless of whether you choose surgery or medical treatment. Higher baseline BMI often correlates with greater absolute weight loss. Mental health and lifestyle habits are also significant factors.

Tirzepatide treatment for obesity results in a 3:1 ratio of fat mass reduction to fat-free mass (FFM) reduction, leading to improved body composition rather than proportional lean tissue loss.

If you are using Tirzepatide for weight loss, you can expect your body composition to improve favorably. The medication targets fat stores more aggressively than lean muscle tissue, resulting in roughly three times more fat loss than muscle loss. This helps maintain your metabolic rate and physical function better than traditional caloric restriction alone, which often depletes lean mass proportionally.

Continued treatment with Tirzepatide maintains significant weight loss and cardiometabolic improvements, whereas discontinuation leads to partial weight regain and loss of benefits, demonstrating that long-term adherence is required to sustain outcomes.

If you are using Tirzepatide for weight loss, understand that it is a long-term treatment, not a short-term fix. Stopping the medication will likely cause you to regain most of the weight you lost. To keep the weight off, you must continue the medication indefinitely, combined with healthy lifestyle habits, just as you would manage high blood pressure with medication.

Short-term GPS-enabled physical activity interventions (≤3 months) produce greater weight loss effects than longer-term interventions (≥6 months).

If you start a fitness tracking program, expect the biggest results in the first 3 months. To maintain weight loss after that, you must actively work to keep the habit, as the 'newness' of the app will wear off. Consider switching to a less intrusive tracking method or adding social accountability to sustain engagement beyond the initial quarter.

Current anti-obesity medications improve weight and metabolic parameters but do not yet have data supporting a reduction in hard cardiovascular outcomes.

While these drugs significantly reduce weight and improve metabolic markers, they have not yet been proven to reduce hard cardiovascular events like heart attacks or strokes. Weight loss itself is a key factor in long-term health.

A higher triglyceride-glucose (TyG) index, serving as a surrogate marker for insulin resistance, is significantly associated with increased risks of composite cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, and incident type 2 diabetes.

Your risk for heart disease and diabetes is closely linked to your insulin resistance, which can be estimated using a simple calculation from your fasting triglyceride and glucose levels. This risk is not uniform; it is significantly higher for people living in low- and middle-income countries. Regular monitoring of these markers can help identify those at high risk for cardiovascular events and diabetes, allowing for earlier intervention.

Clinical staging of obesity should utilize systems like the Edmonton Obesity Staging System (EOSS) or Waist Circumference (WC) thresholds, as BMI alone fails to capture the severity of obesity-related complications and mortality risk in Asian populations.

Do not rely on BMI alone. Ask your doctor to measure your waist circumference and assess your overall health status (blood pressure, blood sugar, etc.) using a staging system like EOSS. This provides a more accurate picture of your health risks, especially if you are Asian and have 'normal' BMI but carry weight around your midsection.

Vegan and low-fat dietary patterns, when implemented as intended, mostly align with 2021 AHA Dietary Guidance but face challenges regarding nutrient adequacy and adherence due to severe restrictions.

If you follow a vegan or low-fat diet, it can support heart health, but you must be careful about nutrient adequacy. Work with a registered dietitian to ensure you are getting enough essential nutrients, especially if you exclude animal products or fats.

Resistance exercise-induced skeletal muscle hypertrophy is primarily regulated by internal biological variables (e.g., mechanotransduction, mTORC1 signaling, ribosomal biogenesis) rather than external programming alone, with internal variables acting as the dominant determinant of the hypertrophic response.

To maximize muscle growth, focus on consistent resistance training that provides mechanical load. Your body's internal biological machinery (signaling pathways, gene expression) will determine how much muscle you build from that load. Don't chase acute hormone spikes or muscle soreness, as these are not the primary drivers of long-term hypertrophy.

Produce prescription programs significantly reduce household food insecurity and improve self-reported health status in both adults and children.

If you are experiencing food insecurity, ask your healthcare provider about produce prescription programs. These programs can provide financial support for buying fruits and vegetables, which may help improve your overall health and reduce stress related to food access.

Intensive lifestyle modification (including meal replacements and frequent counseling) combined with semaglutide does not produce significantly greater long-term weight loss than semaglutide alone with brief counseling, suggesting the medication's efficacy may render intensive behavioral interventions redundant for long-term outcomes.

When taking semaglutide, intensive lifestyle programs (like meal replacements and frequent counseling) do not significantly improve long-term weight loss compared to brief counseling. The medication's effect is so strong that it largely overrides the need for intensive behavioral strategies for weight loss, though lifestyle changes remain important for health.

Incretin-mimetic drugs (IMDs) such as semaglutide and tirzepatide cause significant skeletal muscle mass loss (≥10%) during rapid weight reduction, a loss comparable to 20 years of age-related decline.

If you are taking GLP-1 or GIP/GLP-1 drugs, expect to lose muscle along with fat. This is not just 'water weight'; it is functional tissue. To mitigate this, you must prioritize protein intake and engage in resistance training, as these are the only proven strategies to preserve muscle during rapid weight loss.

Long-term use of GLP-1 receptor agonists (GLP-1RAs) reduces the incidence of knee surgery and slows cartilage loss velocity in knee osteoarthritis (KOA) patients with comorbid type 2 diabetes, primarily mediated by significant weight loss rather than direct anti-inflammatory effects.

If you have knee osteoarthritis and type 2 diabetes, using GLP-1RAs (like semaglutide or liraglutide) for at least two years can significantly reduce your risk of needing knee surgery and slow down cartilage wear. This benefit comes mainly from the weight loss these drugs cause, which reduces stress on your knees. While they also help with pain, the structural protection is largely weight-dependent. To maximize benefits, combine GLP-1RA therapy with resistance training to preserve muscle mass.

Dietary composition, particularly high carbohydrate intake, can reduce post-weight-loss metabolic expenditure by approximately 200 kcal/day compared to higher fat intakes, contributing to weight regain.

After weight loss, be mindful of high-carbohydrate diets, especially if you have insulin resistance. Higher fat or lower carbohydrate intakes may help preserve metabolic rate, making it easier to maintain your weight.

AOM therapy requires monitoring and potential dose reduction of concomitant medications for diabetes and hypertension due to rapid weight loss and improved metabolic parameters.

If you take medication for diabetes or high blood pressure, tell your doctor you are starting an AOM. Your doses may need to be lowered quickly as you lose weight to prevent dangerous drops in blood sugar or blood pressure.

Metformin is the primary first-line oral treatment for type 2 diabetes across all age groups due to its efficacy, versatility, and cost-effectiveness, with benefits extending to cardiovascular and potential anti-neoplastic properties.

Start with metformin as your primary medication. It is the standard, effective, and affordable choice for managing blood sugar. While it may cause mild stomach issues initially, it is generally well-tolerated and helps protect your heart and kidneys over the long term.